1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

US FDA Advisory Committees' Future: Drug-Agnostic Panels, More Debate Time

 
• By Sarah Karlin-Smith

FDA Commissioner Califf and some top deputies are angling for more advisory panels that would influence drug development programs rather than approval decisions. Califf also wants to adjust meeting formats so advisors have more time for in-depth discussions.

boats
The FDA is looking to “float all boats” with future non-drug specific advisory panel topics. • Source: Shutterstock

US Food and Drug Administration Commissioner Robert Califf wants advisory committees spending more time debating drug development topics that apply to multiple products, rather than the typical product-specific events.

Some top FDA career professionals championed the idea along with Califf, who endorsed it during the 13 February Prevision Policy/Friends of Cancer Research Biopharma Congress, as the agency is undertaking a revamp of its advisory committee system

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers